JPRN-jRCT2080223034未知2 期
A phase II study of ABI-007 in combination with Ramucirumab in patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Signed, written informed consent.
- •-Histologically or cytologically confirmed gastric adenocarcinoma.
- •-Eastern Cooperative Oncology Group performance status of 0-1
排除标准
- •-Past history of severe drug hypersensitivity
- •-Patient has pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per CTCAE).
- •-Principal Investigator's (sub investigator's) judgment on ineligibility
研究者
相似试验
已完成
1 期
Phase I clinical study of ABI-007 in combination with gemcitabinepancreatic cancerJPRN-jRCT2080223124Taiho Pharmaceutical Co., Ltd.40
未知
1 期
A Phase I Study of weekly ABI-007 in Combination with TS-1 in Patients with Metastatic Breast CancerMetastatic breast cancerJPRN-jRCT2080221553Taiho Pharmaceutical Co., Ltd.24
进行中（未招募）
1 期
Efficacy of ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer.metastatic pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2013-001463-23-FRGERCOR114
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic adenocarcinoma of the pancreasMedDRA version: 14.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ITABRAXIS BIOSCIENCE LLC AN INDIRECT SUBSIDIARY OF CELGENE CORPORATIO842
已完成
2 期
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast CancerMetastatic Breast CancerNCT00394082Celgene50